SemiVoice

seekingalpha

02/09/2025, 06:00 AM UTC

诺和诺德2024年业绩回顾Novo Nordisk: 2024 Earnings Review

1、诺和诺德2024年业绩超出预期，收入增长25%；2、市场对CagriSema试验结果反应过度，导致股价下跌20%；3、尽管市场反应如此，诺和诺德股价仍具吸引力，因此给予强烈买入评级。

1. Novo Nordisk's 2024 earnings exceeded estimates with 25% revenue growth; 2. The market overreacted to CagriSema trial results, leading to a 20% stock drop; 3. Despite the market's reaction, Novo Nordisk's shares offer attractive returns, leading to a Strong Buy rating.

---

本文由大语言模型（LLM）生成，旨在为读者提供半导体新闻内容的知识扩展（Beta）。